3.70 -0.01 (-0.27%)
SNTS
Stock Details
Last Trade:3.70 Change:-0.01 (-0.27%) Prev Close:3.71 Open: 3.74 Days Range:3.66 – 3.79 52 Week Range: 1.05 - 5.82 Volume:246512 P/E: N/AEPS:-0.07
View AllRecent Alerts 02/10/10
Recent Alert on 02/02/10 at 2:00pm
Unusual 11 Mid-Day Movers 2/2: CITP, BSDM, RTEC, NOA, FSII Higher; FBP, DST, GU, SNTS Lower
Unusual 11 Mid-Day Movers 2/2: CITP, BSDM, RTEC, NOA, FSII Higher; FBP, DST, GU, SNTS Lower
COMSYS IT Partners, Inc. (Nasdaq: CITP) 32.1% HIGHER; Manpower Inc. (NYSE: MAN) announced an agreement to acquire COMSYS IT for $17.65 per share, for a total enterprise value of $431 million, including net debt assumed by Manpower. BSD Medical... Read More
Recent Alert on 12/30/09 at 6:50am
Santarus (SNTS) Submits IND to U.S. FDA to Begin Phase III of Rifamycin SV MMX
Santarus (SNTS) Submits IND to U.S. FDA to Begin Phase III of Rifamycin SV MMX
Recent Alert on 12/30/09 at 6:50am
Santarus (SNTS) Submits IND to U.S. FDA to Begin Phase III of Rifamycin SV MMX
Santarus (SNTS) Submits IND to U.S. FDA to Begin Phase III of Rifamycin SV MMX
Recent Alert on 12/22/09 at 7:00am
Santarus (SNTS) Receives $20M Milestone Payment for ZEGERID U.S. FDA Approval
Santarus (SNTS) Receives $20M Milestone Payment for ZEGERID U.S. FDA Approval
Recent Alert on 12/22/09 at 7:00am
Santarus (SNTS) Receives $20M Milestone Payment for ZEGERID U.S. FDA Approval
Santarus (SNTS) Receives $20M Milestone Payment for ZEGERID U.S. FDA Approval
View AllRecent Press Releases
No Recent Press Releases Available
View AllRecent SEC Filings
No Recent SEC Filings Available
View AllRecent Blog Posts
Blog Posts on 11/16/09 at 10:33am
Santarus, Depomed Poised to Gain from Anticipated Sales of Glumetza
Santarus, Depomed Poised to Gain from Anticipated Sales of Glumetza